Alignment with the FDA enables a planned Q4 NDA submission for AXPAXLI, supported by robust single-trial data showing superior durability and safety in wet AMD. Commercial and operational infrastructure is in place, with broad adoption expected and strong financial resources backing the launch.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.